A prospective, observational, cohort study assessing daratumumab, carfilzomib, elotuzumab, or pomalidomide and their impact on infectious complications in patients with relapsed/refractory multiple myeloma
Latest Information Update: 08 Jan 2021
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Elotuzumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 08 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology